Treats Attention Deficit Hyperactivity Disorder (ADHD). Sold as Adzenys Er, Adzenys Xr-Odt. Every FDA application for this active ingredient: 2 branded and 3 generic.
As of Nov 14, 2026, FDA lists 5 applications for Amphetamine (sold as Adzenys Er, Adzenys Xr-Odt), first approved Jan 27, 2016, with 0 new uses approved and 0 published complete response letters.
| Adzenys XR-ODT | Part D | $1.1M | -4% | 315 |
| Dyanavel XR | Part D | $791K | +10% | 351 |
| Amphetamine Sulfate | Part D | $121K | -6% | 243 |
| Evekeo | Part D | $36K | -51% | 0 |
| Amphetamine ER ODT | Part D | $34K | New | 44 |
| Closed-loop tTIS Targeted of the Nac as an Intervention for MUD PatientsAmphetamine Use Disorders · Shanghai Mental Health Center | Not applicable | Not yet recruiting | Sep 3, 2026 |
| Psilocybin Therapy for Methamphetamine Use Disorder and HIVMethamphetamine Use Disorder, Human Immunodeficiency Virus (HIV) · Nicky Mehtani, MD, MPH | Phase 2 | Recruiting | Aug 11, 2026 |
| Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy DiscontinuationObesity · Massachusetts General Hospital | Phase 4 | Not yet recruiting | Jul 27, 2026 |
| Effects of Stimulant Medications in PTSDAdderall, PTSD · University of Chicago | Phase 1 | Not yet recruiting | Jun 24, 2026 |
| EEG Biomarkers for ADHD Stimulant TreatmentADHD · Boston Children's Hospital | Phase 4 | Not yet recruiting | Jun 16, 2026 |
| Study of Midomafetamine in Healthy AdultsHealthy Volunteers · Resilient Pharmaceuticals | Phase 1 | Active, not recruiting | May 13, 2026 |
| Short-term Effects of Methamphetamine on Residual Latent HIV Disease StudyHIV -1 Infection, Methamphetamine Use · University of California, San Francisco | Phase 4 | Not yet recruiting | May 13, 2026 |
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite AthletesSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes · Enhanced Emirates Limited | Not applicable | Enrolling by invitation | May 6, 2026 |
| Jan 27, 2016 | Adzenys Xr-OdtNDA 204326 · New formulation or manufacturer | Neos Theraps | 8 | Marketed |
| Sep 15, 2017 | Adzenys ErNDA 204325 · New dosage form | Neos Theraps Inc | 1 | Discontinued |
| Jun 22, 2023 | AmphetamineANDA 209253 | Actavis Labs Fl Inc | 3 | Marketed |
| — | AmphetamineANDA 219800 | Granules Pharmaceuticals Inc | 0 | Discontinued |
| — | AmphetamineANDA 220284 | Granules Pharmaceuticals Inc | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
